Advertisement
ARRY vs INO
Which Stock Would AI Choose? Array Technologies (ARRY) vs. Inovio Pharmaceuticals (INO) Stock Comparison
Key Takeaways
- ARRY (Array Technologies) is a solar tracking equipment manufacturer showing improving profitability, a record order book, and positive momentum, while INO (Inovio Pharmaceuticals) is a pre-revenue biotech whose value hinges on a single pending regulatory decision.
- The two companies operate in unrelated sectors—renewable-energy hardware versus DNA medicines—making this comparison a study in contrasting risk profiles rather than direct competition.
- ARRY has reported consecutive earnings beats and raised guidance, whereas INO continues to post net losses with limited cash runway.
- INO carries a binary near-term catalyst (a pending FDA decision around late October 2026), while ARRY's trajectory is shaped by multi-quarter commercial and order-book trends.
- Analyst sentiment leans constructive on both, but ARRY's profitability is already visible while INO's depends on future regulatory and commercial success.
- For additional context, explore ARRY Major News and ARRY Today's Price Move, as well as INO Major News and INO Today's Price Move.
- To see how automated systems are positioning across thousands of tickers, explore the curated Trending AI Robots.
Introduction
Comparing ARRY and INO brings together two companies with almost nothing in common operationally, yet both attract traders seeking a defined catalyst. Array Technologies supplies ground-mount solar tracking systems for utility-scale projects, while Inovio Pharmaceuticals develops DNA-based medicines led by a single regulatory candidate. This stock comparison is relevant to investors weighing a revenue-generating industrial turnaround against a high-risk, pre-revenue biotechnology name. Because their drivers, sector exposure, and risk profiles diverge sharply, evaluating their relative performance and market positioning offers a useful framework for understanding how different types of catalysts translate into share-price behavior.
ARRY Overview and Recent Performance
ARRY, or Array Technologies, manufactures ground-mounting solar tracking systems used in utility-scale and distributed solar energy projects. In recent weeks, the company has reported sequential profitability improvements, with adjusted gross margin expanding and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rising sharply, even as year-over-year revenue declined amid a deliberate shift toward higher-margin domestic business. The company has posted consecutive quarterly earnings beats and built a record order book—reaching roughly $2.4 billion and then $2.5 billion in successive quarters—while surpassing 100 gigawatts of cumulative tracker shipments. Management raised full-year adjusted EPS (earnings per share) guidance, and sell-side firms, including Goldman Sachs, lifted price targets. Broader market activity has favored the name, with a notable one-year share-price gain, reflecting improving execution, new product launches, and disciplined international expansion.
INO Overview and Recent Performance
INO, or Inovio Pharmaceuticals, is a biotechnology company developing DNA medicines targeting HPV (human papillomavirus)-related diseases, cancer, and infectious conditions. Its lead candidate, INO-3107, is being evaluated for recurrent respiratory papillomatosis (RRP), a rare disease of the respiratory tract. In recent weeks, investor attention has centered on the regulatory timeline: the FDA (U.S. Food and Drug Administration) accepted the company's BLA (Biologics License Application) but assigned a standard rather than accelerated review, a development that triggered a sharp selloff late in 2025. The assigned PDUFA (Prescription Drug User Fee Act) target action date falls around late October 2026, making approval a near-term binary event. The company remains loss-making with a modest cash balance, has reduced its workforce to extend runway, and carries elevated short interest, contributing to pronounced share-price volatility and a negative year-to-date return.
Trending AI Robots
Tickeron's Trending AI Robots page is a curated destination showcasing automated trading systems selected for their suitability to current market conditions. While Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, only a subset earns placement in this section. These bots span varied trading styles, strategies, timeframes, performance statistics, and sets of tickers they trade, giving traders a way to observe how algorithmic approaches adapt to shifting volatility and sector rotation. Browsing the page offers insight into which signals and setups the platform's systems currently rank most favorably. If you want to see how automation is responding to today's market, explore Trending AI Robots.
Head-to-Head Comparison
The contrast between ARRY and INO is stark across nearly every dimension. ARRY operates a revenue-generating industrial model with tangible demand visibility through its order book, near-term profitability, and exposure to renewable-energy spending trends; its risks are cyclical, tied to project timing, logistics costs, and policy support. INO, by contrast, generates minimal revenue and remains dependent on regulatory approval and subsequent commercialization of a single product; its risks are binary and clinical, with a thin cash runway and heavy short interest amplifying volatility. On momentum, ARRY has demonstrated multi-quarter improvement and a rising one-year trend, while INO has struggled with a negative one-year return despite analyst price targets implying substantial upside. In short, ARRY offers a more stable but slower-burning setup, whereas INO presents a high-variance catalyst-driven trade.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor ARRY over INO in the current environment. ARRY exhibits more sustained positive momentum, improving fundamentals, and a clearer path to continued earnings growth, all characteristics that tend to score favorably in trend-following models. INO, while carrying a potentially transformative catalyst around its late-October 2026 PDUFA date, displays greater downside volatility, weaker trend consistency, and a less stable fundamental footing. These conclusions are probabilistic rather than definitive, and market conditions can shift rapidly for both names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARRY is a Hold and INO is a Hold.
Momentum Indicator for ARRY turns positive, indicating new upward trend
ARRY saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 75 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on October 27, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in 31 of 41 cases over the following month. The odds of a continued upward trend are 76%.
ARRY moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARRY moved out of overbought territory on November 09, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 19 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 47 cases where ARRY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
INO in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 02, 2026
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 29 of the 33 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 56 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.498). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARRY | INO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 59 | 36 | |
P/E GROWTH RATING 1..100 | 43 | 60 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARRY's Valuation (8) in the Biotechnology industry is significantly better than the same rating for INO (90) in the Medical Specialties industry. This means that ARRY’s stock grew significantly faster than INO’s over the last 12 months.
ARRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ARRY’s stock grew similarly to INO’s over the last 12 months.
ARRY's SMR Rating (100) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that ARRY’s stock grew similarly to INO’s over the last 12 months.
INO's Price Growth Rating (36) in the Medical Specialties industry is in the same range as ARRY (59) in the Biotechnology industry. This means that INO’s stock grew similarly to ARRY’s over the last 12 months.
ARRY's P/E Growth Rating (43) in the Biotechnology industry is in the same range as INO (60) in the Medical Specialties industry. This means that ARRY’s stock grew similarly to INO’s over the last 12 months.
| ARRY | INO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 76% | 2 days ago 75% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 76% |
| Advances ODDS (%) | 9 days ago 76% | 16 days ago 79% |
| Declines ODDS (%) | 3 days ago 89% | 7 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARRY’s FA Score shows that 1 FA rating(s) are green while INO’s FA Score has 0 green FA rating(s).
- ARRY’s FA Score: 1 green, 4 red.
- INO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARRY’s TA Score shows that 5 TA indicator(s) are bullish while INO’s TA Score has 5 bullish TA indicator(s).
- ARRY’s TA Score: 5 bullish, 5 bearish.
- INO’s TA Score: 5 bullish, 5 bearish.
Price Growth
ARRY (@Alternative Power Generation) experienced а -2.44% price change this week, while INO (@Biotechnology) price change was -8.95% for the same time period.
The average weekly price growth across all stocks in the @Alternative Power Generation industry was +1.25%. For the same industry, the average monthly price growth was -6.32%, and the average quarterly price growth was -44.58%.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ARRY is expected to report earnings on Mar 03, 2027.
INO is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Alternative Power Generation (+1.25% weekly)The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
INO and
Correlation & Price change
A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INO | 1D Price Change % | ||
|---|---|---|---|---|
| INO | 100% | +1.72% | ||
| AXON - INO | 53% Loosely correlated | +4.26% | ||
| ARRY - INO | 52% Loosely correlated | +9.94% | ||
| LPCN - INO | 41% Loosely correlated | N/A | ||
| AMRN - INO | 39% Loosely correlated | -0.34% | ||
| PCSA - INO | 38% Loosely correlated | N/A | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DRMP | 15.52 | 1.26 | +8.80% |
| Tuttle Capital Memory Stack Income Blast ETF (DRMP) | |||
| EVIM | 52.30 | 0.06 | +0.11% |
| Eaton Vance Intermediate Municipal Income ETF (EVIM) | |||
| APRZ | 39.72 | N/A | N/A |
| TrueShares Structured Outcome (April) ETF (APRZ) | |||
| EPP | 55.97 | -0.02 | -0.04% |
| iShares MSCI Pacific ex-Japan ETF (EPP) | |||
| NMI | 9.59 | -0.02 | -0.19% |
| Nuveen Municipal Income | |||